No connection

Search Results

Earnings Score 52 Neutral

Roche Navigates Currency Headwinds with Strategic Pivot to U.S. and Weight-Loss Markets

Apr 23, 2026 06:50 UTC
RHHBY, ROG.SW
Medium term

Swiss pharmaceutical giant Roche reported a decline in first-quarter sales due to a strong Swiss franc and generic competition. Despite reported losses, the company is aggressively expanding its U.S. footprint and targeting the lucrative obesity drug sector.

  • Q1 sales fell 5% to 14.7 billion Swiss francs
  • Constant currency sales grew 6%; USD sales grew 9%
  • Strong Swiss franc acted as a significant drag on reported earnings
  • Strategic focus shifting toward U.S. investments and acquisitions
  • Developing CT-388 to enter the weight-loss drug market
  • Aiming for top-three global position in obesity treatment

Roche reported first-quarter sales of 14.7 billion Swiss francs ($18.7 billion), representing a 5% year-on-year decline. The company attributed the drop primarily to the appreciation of the Swiss franc and increasing generic competition for its legacy drug portfolio. While the reported figures show a decline, the company's performance on a constant currency basis tells a different story, with sales increasing by 6%. When measured in U.S. dollars, sales grew by 9%, highlighting the disparity between operational growth and currency translation effects. CEO Thomas Schinecker emphasized the company's commitment to the United States, noting that the majority of Roche's spending and debt are U.S.-based. This strategy includes recent acquisitions in the region to hedge against currency volatility and capture growth in the world's largest healthcare market. To counter the looming loss of exclusivity for several key medicines by the end of the decade, Roche is betting heavily on the weight-loss market. The company is developing an experimental drug, CT-388, with the ambition of securing a double-digit market share and becoming one of the top three global players alongside incumbents Novo Nordisk and Eli Lilly.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 45 Bullish

NextEra Energy Reaffirms Long-Term Growth Targets and FY2026 Guidance

Apr 23, 12:09

Score 45 Bullish

Ryder System Raises 2026 Full-Year Guidance on Strategic Gains

Apr 23, 12:04

Score 42 Bullish

United Bankshares Reports Strong Q1 Growth with Profit Surge

Apr 23, 12:00

Score 35 Bullish

Dime Community Bancshares Reports Strong Q1 Growth in Profit and Revenue

Apr 23, 11:58

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile